Prospective and randomized controlled study on the efficacy and safety of ipragliflozin and metformin to visceral fat reduction for the patients being treated with DPP-4 inhibitors for poor glycemic controlled type-2 diabetes
Phase of Trial: Phase III
Latest Information Update: 17 May 2017
At a glance
- Drugs Ipragliflozin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 16 May 2017 Status changed from active, no longer recruiting to completed.
- 12 May 2017 Planned End Date changed from 30 Apr 2017 to 12 May 2017.
- 11 Oct 2016 Status changed from recruiting to active, no longer recruiting.